Short Interest in TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) Increases By 52.4%

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) was the recipient of a significant growth in short interest in July. As of July 31st, there was short interest totaling 12,050 shares, a growth of 52.4% from the July 15th total of 7,908 shares. Based on an average daily volume of 3,956 shares, the short-interest ratio is presently 3.0 days.

Hedge Funds Weigh In On TriSalus Life Sciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Cerity Partners LLC acquired a new stake in TriSalus Life Sciences in the 4th quarter valued at $1,374,000. Citadel Advisors LLC raised its stake in TriSalus Life Sciences by 439.0% during the third quarter. Citadel Advisors LLC now owns 126,876 shares of the company’s stock worth $199,000 after acquiring an additional 103,336 shares in the last quarter. Aristeia Capital L.L.C. acquired a new position in TriSalus Life Sciences during the fourth quarter worth $43,000. Finally, Fort Baker Capital Management LP bought a new position in shares of TriSalus Life Sciences during the fourth quarter valued at $44,000.

TriSalus Life Sciences Stock Up 78.6%

NASDAQ TLSIW traded up $0.44 during trading on Tuesday, reaching $1.00. 220 shares of the company traded hands, compared to its average volume of 5,207. The stock’s 50 day moving average price is $0.82 and its two-hundred day moving average price is $1.00. TriSalus Life Sciences has a 1-year low of $0.44 and a 1-year high of $2.29.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage medical device company focused on developing minimally invasive technologies to enhance the precision and efficacy of cancer radiation therapy. The company’s lead product, the TriMark™ Tissue Marker System, is designed to provide high-visibility soft-tissue fiducial markers that assist oncologists in accurately targeting tumors during radiotherapy. By deploying bio-absorbable markers directly into tumor beds, TriSalus aims to improve treatment planning, patient comfort and long-term follow-up imaging.

Founded in 2015 and headquartered in Plymouth, Minnesota, TriSalus Life Sciences pursues a platform approach to oncology treatment, with research and development efforts centered on novel delivery devices and advanced imaging solutions.